Archives of Drug Information最新文献

{"title":"Epoetin Theta with a New Dosing Schedule in Anaemic Cancer Patients Receiving Nonplatinum-Based Chemotherapy: A Randomised Controlled Trial","authors":"Sergei A. Tjulandin MD,&nbsp;Peter Bias MD,&nbsp;Reiner Elsässer Dipl. Stat,&nbsp;Beate Gertz PhD,&nbsp;Erich Kohler PhD,&nbsp;Anton Buchner PhD","doi":"10.1111/j.1753-5174.2011.00035.x","DOIUrl":"10.1111/j.1753-5174.2011.00035.x","url":null,"abstract":"<p><b>Introduction. </b> Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to chemotherapy. A new r-HuEPO, Epoetin theta (Eporatio^®), was investigated and compared to placebo in a randomised, double-blind clinical trial in adult cancer patients receiving nonplatinum-based chemotherapy. The primary efficacy endpoint was the responder rate (complete haemoglobin (Hb) response, i.e., Hb increase ≥2 g/dl) without the benefit of a transfusion within the previous 4 weeks.</p><p><b>Research Design and Methods. </b> 186 patients were randomised to s.c. treatment for 12 weeks with either Epoetin theta (N = 95) or placebo (N = 91). The starting dose was 20,000 IU once weekly Epoetin theta or placebo.</p><p><b>Results. </b> The incidence of complete Hb responders was significantly higher in the Epoetin theta group than in the placebo group (72.6 vs. 25.3%, <i>P</i> &lt; 0.0001). More patients in the placebo group than in the Epoetin theta group received blood transfusions after randomisation (23 patients, 25.3% vs. 13 patients, 13.7%, <i>P</i> = 0.0277). The majority of patients with a complete Hb response had 20,000 IU/week as their maximum dose prior to response, indicating that a dose of 20,000 IU is an appropriate starting dose. The overall frequencies of adverse events (AEs) were similar in both treatment groups. Hypertension was the only AE that was more frequent in the Epoetin theta group compared to the placebo group (8.4 vs. 1.1%).</p><p><b>Conclusions. </b> Epoetin theta showed a superior efficacy to placebo in terms of complete Hb response without blood transfusion within the previous 4 weeks. Treatment with Epoetin theta resulted in a statistically significant increase in mean haemoglobin levels compared to placebo. The overall frequencies of adverse events were similar in both treatment groups.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"4 3","pages":"33-41"},"PeriodicalIF":0.0,"publicationDate":"2011-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2011.00035.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30228966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 in Japanese Patients with Solid Tumors","authors":"Taito Esaki,&nbsp;Takashi Seto,&nbsp;Hiroshi Ariyama,&nbsp;Shuji Arita,&nbsp;Chinatsu Fujimoto,&nbsp;Koichiro Tsukasa,&nbsp;Takuro Kometani,&nbsp;Kaname Nosaki,&nbsp;Fumihiko Hirai,&nbsp;Katsuro Yagawa","doi":"10.1111/j.1753-5174.2011.00034.x","DOIUrl":"10.1111/j.1753-5174.2011.00034.x","url":null,"abstract":"<p><b>Introduction. </b> AZD4877 is a potent Eg5 inhibitor that has been shown to have an acceptable tolerability profile in a Phase I study of Western patients with solid tumors. This study was conducted to evaluate the safety, pharmacokinetic (PK) profile, maximum tolerated dose (MTD) and efficacy of AZD4877 in a Japanese population with solid tumors.</p><p><b>Methods. </b> In this Phase I, open-label, dose-escalation study, AZD4877 (10, 15, 20 or 25 mg) was administered as a 1-hour intravenous infusion on days 1, 8 and 15 of repeated 28-day cycles to Japanese patients with advanced solid tumors. Adverse events (AEs) were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0. PK variables were assessed pre- and post dosing. The MTD of AZD4877 was determined by evaluating dose-limiting toxicities (DLTs). Efficacy was evaluated by assessing best response according to Response Evaluation Criteria In Solid Tumors version 1.0.</p><p><b>Results. </b> Of the 21 patients enrolled, 18 received at least one dose of AZD4877 (N = 3 in both the 10 and 15 mg cohorts, N = 6 in both the 20 and 25 mg cohorts). The most commonly reported AEs were fatigue and nausea (39% of patients each). One patient in each of the 20 and 25 mg cohorts experienced a DLT (neutropenia and febrile neutropenia). Dose escalation was halted at 25 mg and the MTD was not defined in this population. CTCAE grade ≥3 abnormal laboratory findings/vital signs were reported in 12 patients, with neutropenia (56%) and leukopenia (44%) being the most commonly reported. Exposure to AZD4877 was not fully dose proportional and AZD4877 clearance and elimination half-life appeared independent of dose. The best response to AZD4877 was stable disease in five of 16 evaluable patients.</p><p><b>Conclusion. </b> AZD4877 up to doses of 25 mg was well tolerated in Japanese patients. There was little evidence of clinical efficacy.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"4 2","pages":"23-31"},"PeriodicalIF":0.0,"publicationDate":"2011-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2011.00034.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30011651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Ciprofloxacin a Substrate of P-glycoprotein?","authors":"Miki Susanto Park,&nbsp;Hideaki Okochi,&nbsp;Leslie Z Benet","doi":"10.1111/j.1753-5174.2010.00032.x","DOIUrl":"https://doi.org/10.1111/j.1753-5174.2010.00032.x","url":null,"abstract":"<p><p>INTRODUCTION: Studies using MDCKII and LLC-PK1 cells transfected with MDR1 cDNA indicate that ciprofloxacin is not a substrate of P-glycoprotein. However, our data has shown that transport studies done using different P-gp overexpressing cell lines (MDCKI-MDR1, MDCKII-MDR1 and L-MDR1), could lead to contradictory conclusion on whether a compound is a substrate of P-gp. The aim of our study was to determine if ciprofloxacin is indeed not a P-glycoprotein substrate using MDCKI cells transfected with human MDR1 cDNA. METHODS: Semi-quantitative RT-PCR was used to determine the mRNA level of MDR1 while Western blot was performed to determine the protein expression level of P-gp, MRP1 and MRP2 in various cells. Ciprofloxacin bidirectional transport studies were performed in MDCKI, MDCKI-MDR1, MDCKII, MDCKII-MDR1, MDCKII-MRP2, LLC-PK1, L-MRP1 and L-MDR1 cells. RESULTS: Ciprofloxacin showed net secretion in MDCKI-MDR1 but net absorption in MDCKI cells. Various P-gp inhibitors decreased the B to A and increased the A to B transport of ciprofloxacin in MDCKI-MDR1 cells while having no effect in MDCKI cells. The B to A transport of ciprofloxacin in MDCKI-MDR1 cells was not affected by non-P-gp inhibitors. In the presence of indomethacin, ciprofloxacin showed net secretion instead of net absorption in MDCKI cells while in the presence of probenecid and sulfinpyrazone, there was no net secretion and absorption. There was no difference in ciprofloxacin transport between MDCKII and MDCKII-MDR1, LLC-PK1 and L-MDR1, LLC-PK1 and L-MRP1 and MDCKII and MDCKII-MRP2. CONCLUSIONS: Transport data in MDCKI and MDCKI-MDR1 cells indicate that ciprofloxacin is a substrate of P-gp but data from MDCKII, MDCKII-MDR1, LLC-PK1 and L-MDR1 cells indicate that ciprofloxacin is not a substrate of P-gp. Vinblastine, a well-known P-gp substrate, also did not show differences between LLC-PK1 and L-MDR1 cells. Further studies need to be performed to characterize these P-gp overexpressing cell lines and the transport of ciprofloxacin.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"4 1","pages":"1-9"},"PeriodicalIF":0.0,"publicationDate":"2011-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2010.00032.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29883402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hydrocortisone Diffusion Through Synthetic Membrane, Mouse Skin, and Epiderm™ Cultured Skin.","authors":"John Mark Christensen,&nbsp;Monica Chang Chuong,&nbsp;Hang Le,&nbsp;Loan Pham,&nbsp;Ehab Bendas","doi":"10.1111/j.1753-5174.2010.00033.x","DOIUrl":"https://doi.org/10.1111/j.1753-5174.2010.00033.x","url":null,"abstract":"<p><p>OBJECTIVES: The penetration of hydrocortisone (HC) from six topical over-the-counter products along with one prescription cream through cultured normal human-derived epidermal keratinocytes (Epiderm™), mouse skin and synthetic nylon membrane was performed as well as the effect hydrating the skin by pre-washing was explored using the Upright Franz Cell. METHOD AND RESULTS: Permeation of HC through EpiDerm™, mouse skin and synthetic membrane was highest with the topical HC gel formulation with prewash treatment of the membranes among seven products evaluated, 198 ± 32 µg/cm(2), 746.32 ± 12.43 µg/cm(2), and 1882 ± 395.18 µg/cm(2), respectively. Pre-washing to hydrate the skin enhanced HC penetration through EpiDerm™ and mouse skin. The 24-hour HC released from topical gel with prewash treatment was 198.495 ± 32 µg/cm(2) and 746.32 ± 12.43 µg/cm(2) while without prewash, the 24-h HC released from topical gel was 67.2 ± 7.41 µg/cm(2) and 653.43 ± 85.62 µg/cm(2) though EpiDerm™ and mouse skin, respectively. HC penetration through synthetic membrane was ten times greater than through mouse skin and EpiDerm™. Generally, the shape, pattern, and rank order of HC diffusion from each commercial product was similar through each membrane.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"4 1","pages":"10-21"},"PeriodicalIF":0.0,"publicationDate":"2011-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2010.00033.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29883403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dose Proportionality of Telcagepant after Administration of Single Oral and Intravenous Doses in Healthy Adult Subjects","authors":"Tae H. Han PhD,&nbsp;Rebecca L. Blanchard PhD,&nbsp;John Palcza MS,&nbsp;Ashley Martucci BS,&nbsp;Cynthia M. Miller-Stein BS,&nbsp;Maria Gutierrez MD,&nbsp;Deborah Panebianco MS,&nbsp;Ronda K. Rippley PhD,&nbsp;Christopher Lines PhD,&nbsp;M. Gail Murphy MD","doi":"10.1111/j.1753-5174.2010.00031.x","DOIUrl":"10.1111/j.1753-5174.2010.00031.x","url":null,"abstract":"<p><b>Introduction. </b> Telcagepant (MK-0974) is a novel, orally active and selective CGRP receptor antagonist being investigated for acute treatment of migraine. Early clinical data suggested greater than dose proportional increases in exposure following oral administration. The aim of the present studies was to definitively characterize the oral and IV dose proportionality of telcagepant.</p><p><b>Methods. </b> Healthy adult subjects were enrolled in two separate open-label randomized dose proportionality studies: 1) single oral dose crossover from 50 to 600 mg (N = 19); 2) single IV dose parallel group from 5 to 250 mg (N = 10 per dose). Blood samples were collected at time points from 0 to 48 hours postdose.</p><p><b>Results. </b> Telcagepant was rapidly absorbed with a T_max of approximately 1 to 2 hours after oral administration. The terminal half-life was approximately 8 to 9 hours after IV dosing and approximately 4 to 7 hours after oral dosing. Oral administration of telcagepant resulted in greater than dose proportional increases in exposure, while IV administration resulted in approximately dose proportional increases in exposure.</p><p><b>Conclusions. </b> Telcagepant was generally well tolerated. Oral telcagepant exhibits non-linear pharmacokinetics.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"3 4","pages":"55-62"},"PeriodicalIF":0.0,"publicationDate":"2010-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2010.00031.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29586566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epoetin Theta in Anaemic Cancer Patients Receiving Platinum-Based Chemotherapy: A Randomised Controlled Trial","authors":"Sergei A. Tjulandin MD,&nbsp;Peter Bias MD,&nbsp;Reiner Elsässer Dipl.Stat.,&nbsp;Beate Gertz PhD,&nbsp;Erich Kohler PhD,&nbsp;Anton Buchner PhD","doi":"10.1111/j.1753-5174.2010.00030.x","DOIUrl":"10.1111/j.1753-5174.2010.00030.x","url":null,"abstract":"<p><b>Introduction. </b> Recombinant human erythropoietin (r-HuEPO) is used to treat symptomatic anaemia due to chemotherapy. A new r-HuEPO, Epoetin theta (Eporatio^®), was investigated and compared to placebo and Epoetin beta in a randomised, double-blind clinical trial in adult cancer patients receiving platinum-based chemotherapy, using a fixed weekly starting dose of 20,000 IU Epoetin theta. The primary efficacy endpoint was the responder rate (complete Hb response, Hb increase ≥ 2 g/dL).</p><p><b>Research Design and Methods. </b> 223 patients were randomised to s.c. treatment for 12 weeks with either Epoetin theta (<i>n</i> = 76) once per week, Epoetin beta (<i>n</i> = 73) three times per week or placebo (<i>n</i> = 74). The starting dose was 20,000 IU once weekly Epoetin theta or 450 IU/kg_BW per week Epoetin beta administered in 3 equal weekly doses.</p><p><b>Results. </b> In the Epoetin theta group were significantly more responders than in the placebo group (65.8 vs. 20.3%, <i>P</i> &lt; 0.0001). Epoetin beta was also more effective than placebo (71.2 vs. 20.3%, <i>P</i> &lt; 0.0001). The mean weekly dose at the time of complete Hb response was lower in the Epoetin theta group (30,000 IU) than in the Epoetin beta group (42,230 IU). Epoetin theta was clearly more effective than placebo.</p><p><b>Conclusion. </b> This small study showed, that Epoetin theta is a safe and effective treatment of symptomatic anaemia due to platinum-based chemotherapy in cancer patients.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"3 3","pages":"45-53"},"PeriodicalIF":0.0,"publicationDate":"2010-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2010.00030.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29681142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bioequivalence of the 4-mg Oral Granules and Chewable Tablet Formulations of Montelukast.","authors":"Barbara Knorr,&nbsp;Alan Hartford,&nbsp;Xiujiang Susie Li,&nbsp;Amy Yifan Yang,&nbsp;Gertrude Noonan,&nbsp;Elizabeth Migoya","doi":"10.1111/j.1753-5174.2010.00029.x","DOIUrl":"https://doi.org/10.1111/j.1753-5174.2010.00029.x","url":null,"abstract":"<p><p>PURPOSE: The primary objective of the studies was to demonstrate bioequivalence between the oral granules formulation and chewable tablet of montelukast in the fasted state. Effect of food on the pharmacokinetics of the oral granules was also evaluated. METHODS: The Formulation Biocomparison Study (Study 1) and the Final Market Image Study (Study 2) each used an open-label, randomized, 3-period crossover design where healthy adult subjects (N = 24 and 30, respectively) received montelukast as a single 4-mg dose of the oral granules formulation and a 4-mg chewable tablet fasted, and a single 4-mg dose of the oral granules formulation with food (on 2 teaspoons of applesauce [Study 1] or after consumption of a high-fat breakfast [Study 2]). The formulations were to be considered bioequivalent if the 90% confidence intervals (CIs) for geometric mean ratios (GMRs) (oral granules/chewable tablet) for the AUC(0-infinity) and C(max) of montelukast were within the prespecified comparability bounds of (0.80, 1.25). For the food-effect assessment in Study 1, comparability bounds were prespecified as (0.50, 2.00) only for the 90% CI of the GMR (oral granules fed/oral granules fasted) for the AUC(0-infinity) of montelukast; the 90% CI of the GMR for the C(max) of montelukast, however, also was computed. In Study 2, 90% CIs of the GMRs (oral granules fed/oral granules fasted) for the AUC(0-infinity) and C(max) of montelukast were computed; comparability bounds were not prespecified. RESULTS: Comparing the exposure of the formulations, the 90% CIs of the GMRs for AUC(0-infinity) and C(max) were within the prespecified bound of (0.80, 1.25). For AUC(0-infinity), the GMRs (90% CI) for Study 1 and Study 2 were 1.01 (0.92, 1.11) and 0.95 (0.91, 0.99), respectively. For C(max), respective values were 0.99 (0.86, 1.13) and 0.92 (0.84, 1.01). When the oral granules formulation was administered with food, 90% CIs of the GMRs for both AUC(0-infinity) and C(max) in both studies were contained within the interval of (0.50, 2.00). CONCLUSIONS: The 4-mg oral granules and 4-mg chewable tablet formulations of montelukast administered in the fasted state are bioequivalent. Single 4-mg doses of the oral granules formulation and the chewable tablet of montelukast are generally well tolerated.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"3 2","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2010.00029.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29169270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of 4-Aminopyridine on Action Potential Parameters in Isolated Dog Purkinje Fibers","authors":"George Thomas PhD,&nbsp;Brian Klatt BS,&nbsp;Andrew Blight PhD","doi":"10.1111/j.1753-5174.2009.00027.x","DOIUrl":"10.1111/j.1753-5174.2009.00027.x","url":null,"abstract":"<p><b>Introduction. </b> 4-Aminopyridine (fampridine), a potassium channel blocker, has demonstrated efficacy in improving lower extremity strength and walking speed in patients with multiple sclerosis. Since <i>in vitro</i> electrophysiologic studies are recommended for evaluating a drug's potential to prolong the QT interval and induce such cardiac arrhythmias as Torsades de Pointes, we examined the electrophysiologic effects of 4-aminopyridine (0.5, 5.0, 50, and 500 µM) on isolated canine Purkinje fibers.</p><p><b>Methods. </b> Microelectrodes monitored the resting membrane potential, overshoot, amplitude of action potential (AP), and maximal rate of depolarization of the AP upstroke in Purkinje fibers stimulated at 0.5 and 1.0 Hz.</p><p><b>Results. </b> None of the above variables were altered in the presence of 4-aminopyridine. The AP duration at 30%, 50%, and 90% repolarization was also monitored, with only the 500-µM concentration at the 1.0-Hz frequency significantly increasing these values with respect to baseline (<i>P</i> &lt; 0.05). However, the small sample size (N = 4) was small. The proportional increases, and their 95% confidence intervals, were 90.8% (−36.4%, 218.0%), 25.8% (11.9%, 39.7%), and 22.0% (14.9%, 29.1%) for APD 30%, 50%, and 90% repolarization, respectively. Reverse rate dependence was not observed, suggesting inhibition of ion channels other than those contributing to QT interval prolongation.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"3 1","pages":"19-25"},"PeriodicalIF":0.0,"publicationDate":"2010-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2009.00027.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28953713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate","authors":"Heribert Knechten MD,&nbsp;Thomas Lutz MD,&nbsp;Piotr Pulik MD,&nbsp;Teodoro Martin MD,&nbsp;Andre Tappe PhD,&nbsp;Hans Jaeger MD","doi":"10.1111/j.1753-5174.2009.00028.x","DOIUrl":"10.1111/j.1753-5174.2009.00028.x","url":null,"abstract":"<p><b>Objective. </b> To evaluate the safety, tolerability, and efficacy of ritonavir-boosted saquinavir 1000/100 mg twice daily administered as a 500 mg film-coated tablet in HIV-1-infected patients.</p><p><b>Methods. </b> In this open-label, observational, 24-week survey conducted in 8 European countries, eligible HIV-infected participants had been prescribed saquinavir/ritonavir in combination with other nonprotease inhibitor (PI) antiretroviral agents as part of their HIV treatment regimen. The safety (grade 3 or 4 adverse events [AEs]), tolerability (by an investigator-reported subjective rating system), and efficacy (the percentage of participants with &lt;50 and &lt;400 copies/mL HIV RNA and change from baseline in mean CD4+ cell count) were analyzed for the overall study population and 7 subpopulations.</p><p><b>Results. </b> The enrolled population included 2122 participants with 1908 completing the study; 44 (2.1%) withdrew prematurely because of AEs, including 7 nontreatment-related deaths. There were 33 grade 3 or 4 AEs in 29 (1.4%) participants; 7 AEs in 7 (0.3%) participants were considered treatment-related. Tolerability was reported to be “very good” or “good” in 42% and 25% of participants, respectively. From baseline to week 24, the proportion of participants with HIV RNA &lt;50 copies/mL increased from 31.2% to 47.6% and the proportion with &lt;400 copies/mL increased from 42.5% to 61.4%; the mean CD4+ cell count increased by 75 cells/µL. In the subpopulation analysis, the greatest efficacy benefits occurred in participants who were treatment-naïve and in those not having received prior PI therapy.</p><p><b>Conclusions. </b> Treatment with the saquinavir 500 mg film-coated tablet resulted in few grade 3 or 4 AEs and was well tolerated and effective in a broad population of patients.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"3 1","pages":"26-36"},"PeriodicalIF":0.0,"publicationDate":"2010-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2009.00028.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28953714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efalizumab in the Treatment of Scalp, Palmoplantar and Nail Psoriasis: Results of a 24-Week Latin American Study","authors":"María Denise Takahashi,&nbsp;Edgardo Néstor Chouela,&nbsp;Gladys Leon Dorantes,&nbsp;Ana Maria Roselino,&nbsp;Jesùs Santamaria,&nbsp;Miguel Angel Allevato,&nbsp;Tania Cestari,&nbsp;Maria Eugenia Manzanera De Aillaud,&nbsp;Fernando Miguel Stengel,&nbsp;Daiana Licu","doi":"10.1111/j.1753-5174.2009.00025.x","DOIUrl":"10.1111/j.1753-5174.2009.00025.x","url":null,"abstract":"<p><b>Introduction. </b> Plaque-type psoriasis affecting the nails, scalp, hands or feet can often be difficult to treat; for example, topical treatments and phototherapy may not penetrate the nail plate or scalp. The objective of this large, international, multicentre study was to investigate the efficacy of efalizumab in a Latin American population of adult patients with moderate-to-severe chronic plaque psoriasis who were candidates for systemic therapy or phototherapy.</p><p><b>Methods. </b> Eligible patients were enrolled in a 24-week, open-label, single-arm, Phase IIIb/IV study of continuous treatment with subcutaneous efalizumab, 1.0 mg/kg/wk. Involvement of the nails, scalp, or hands or feet was assessed using the Nail Psoriasis Severity Index (NAPSI), the Psoriasis Scalp Severity Index (PSSI), or the Palmoplantar Pustulosis Psoriasis Area and Severity Index (PPPASI), respectively. Missing data were handled using a last observation carried forward or nonresponder imputation approach.</p><p><b>Results. </b> Of the 189 patients who received treatment, 112 patients had nail involvement, 172 had scalp involvement, and 19 had palmoplantar disease at baseline. At Week 24, ≥50% improvement on the NAPSI, PSSI and PPPASI was observed in 31%, 71% and 68% of patients, respectively, whereas ≥75% improvement on these scores was observed in 17%, 52% and 63%, respectively. Descriptive statistics showed lower NAPSI-75 and higher PSSI-75 and -50 response rates among patients with higher baseline scores.</p><p><b>Conclusions. </b> This open-label, uncontrolled study provides supportive evidence of the potential of efalizumab as a treatment for nail, scalp and palmoplantar psoriasis.</p>","PeriodicalId":8181,"journal":{"name":"Archives of Drug Information","volume":"3 1","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2010-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/j.1753-5174.2009.00025.x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"28953711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}